Albireo Pharma Inc Revenu
Quel est le Revenu de Albireo Pharma Inc?
Le Revenu de Albireo Pharma Inc est $57.391M
Quelle est la définition de Revenu?
Le revenu est le revenu qu'une entreprise tire de ses activités commerciales normales, généralement de la vente de biens et de services aux clients.
Revenue is also referred to as sales or turnover. Some companies receive revenue from interest, royalties, or other fees. Revenue may refer to business income in general, or it may refer to the amount, in a monetary unit, earned during a period of time, as in "Last year, Company X had revenue of $42 million". Profits or net income generally imply total revenue minus total expenses in a given period.
In accounting, revenue is often referred to as the "top line" due to its position on the income statement at the very top. This is to be contrasted with the "bottom line" which denotes net income.
Revenu des entreprises dans Health Care secteur sur NASDAQ par rapport à Albireo Pharma Inc
Que fait Albireo Pharma Inc?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Entreprises avec revenu similaire à Albireo Pharma Inc
- The Environmental a Revenu de AUD$57.065M
- Onelife Capital Advisors a Revenu de ₨57.086M
- APN Convenience Retail REIT a Revenu de AUD$57.240M
- Urban&Civic plc a Revenu de £57.241M
- Huisheng International a Revenu de ¥57.260M
- JKX Oil & Gas Plc a Revenu de $57.333M
- Albireo Pharma Inc a Revenu de $57.391M
- Umiya Tubes a Revenu de ₨57.477M
- Steppe Gold a Revenu de $57.510M
- CSP a Revenu de $57.512M
- Electra Private Equity Plc a Revenu de £57.600M
- Limeade a Revenu de $57.660M
- UroGen Pharma a Revenu de $57.693M